Drug Database
SH

SH-U-454

✓ Approved

Bayer AG · Small Molecule · Small Molecule

What is SH-U-454?

SH-U-454 is a small molecule developed by Bayer AG. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyBayer AG
Drug ClassSmall Molecule, Imaging Agents
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Bayer AG

Therapeutic Indications

SH-U-454 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Cardiac disordersArteriosclerosis coronary artery✓ Approved

Related Research Articles

PubMedPakistan journal of medical sciences2026-08-30

Ureaplasma parvum meningitis in neonates: A retrospective case study and literature review.

Yan Fang F, Lin Meifang M, Fu Qinqin Q, Gao Yi Y et al.

To investigate the clinical characteristics and advances in diagnosis and treatment of neonatal Ureaplasma parvum (U. parvum) meningitis. Clinical manifestations, diagnosis, treatment, and follow-up data of a neonate with persistent fever, normal blood routine, but persistently abnormal cerebrospinal fluid (CSF) results due to U. parvum meningitis were retrospectively analyzed. A literature review was conducted to identify relevant studies reporting on neonatal U. parvum meningitis published until May 2025. A male infant born at 35+2 weeks of gestation with eight hours of premature rupture of membranes (PROM) was admitted at 17 days of age with persistent fever. The routine blood test was normal, while the CSF suggested purulent meningitis. Empirical treatment was ineffective, and metagenomic next-generation sequencing (mNGS) of CSF confirmed U. parvum meningitis. The infant recovered after three weeks of azithromycin treatment, but a language delay was found at two-year follow-up. The literature review identified 16 previously reported cases of U. parvum meningitis, which were combined with the current case, totaling 17 cases. Main manifestations included fever and convulsions, or initial circulatory and respiratory symptoms. CSF in the included studies showed leukocytosis, decreased glucose, and elevated protein. Diagnosis was mainly based on mNGS, and the predominant treatment consisted of macrolides, sometimes combined with quinolones, for 3-10 weeks. Two patients relapsed after drug withdrawal, and one had elevated liver enzymes. Major neurological complications included lateral ventricular dilatation and hydrocephalus, cerebral hemorrhage, infarction, malacia, and herniation. Most cases had a favorable prognosis, with rare developmental delay. Clinical manifestations of neonatal U. parvum meningitis are nonspecific. Some patients present with normal blood routine but purulent CSF. U. parvum meningitis should be suspected in patients with poor response to empirical antibiotics and confirmed by CSF mNGS. Macrolides are biologically rational and commonly used for neonatal U. parvum meningitis; however, the optimal regimen and duration remain unclear due to limited and heterogeneous case-based evidence.

PMID 42668932
Read full article →
PubMedMolecular therapy. Oncology2026-08-30

Additive effect of Ruta graveolens bioactive phytoconstituents and cisplatin through PKC/MEK/ERK pathway in glioblastoma.

Romano Grazia G, Morgera Valentina V, Pezone Antonio A, Messina Samantha S et al.

Glioblastoma multiforme (GBM) is a lethal malignancy with limited therapeutic options. Its aggressive progression and resistance to standard therapy necessitate the development of novel therapeutic strategies. Plant-based compounds have emerged as promising candidates for therapeutic development modulating key targets in cancer. The Ruta graveolens displays anti-inflammatory, analgesic, and antimicrobial properties. Herein, we report the anticancer potential of R. graveolens water extract (RGWE) on long-term cultures of human glioblastoma and elucidate the regulatory mechanisms driving its effect. Secondary stabilized cell cultures (U-87 MG, T98MG, and U-138 MG) and primary cell culture (FCN, MZC, and GL18-15) were either treated with RGWE and/or cis-diamminedichloroplatinum (cisplatin, CDDP). Cytostatic responses were assessed by cell viability (TB exclusion test), cell cycle (propidium iodide [PI] staining), and apoptosis (Annex-V and caspase-3) assays. We demonstrate that RGWE slows U-87 MG growth without affecting apoptosis and arrests the cell cycle in the G2/M phase. Mechanistically, RGWE interferes with PKC/MEK/ERK signaling pathway, as assessed by western blot analysis, through PKC inhibition in its active form. Furthermore, the combination of RGWE and cisplatin enables the use of a sublethal dose of the latter (0.2 μg/mL), thereby reducing cytotoxicity and the resistance to the drug. These findings reveal a novel mechanism by which RGWE controls glioblastoma growth, highlighting the therapeutic potential of targeting the PKC/MEK/ERK axis in glioma treatment.

PMID 42668569
Read full article →
PubMedJournal of gastroenterology2026-08-30

Efficacy and safety of upadacitinib for Crohn's disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies.

Chen Minhu M, Gao Xiang X, Watanabe Kenji K, Fujii Toshimitsu T et al.

Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of moderate-to-severe Crohn's disease (CD). This post hoc analysis reports the efficacy and safety of upadacitinib for CD in patients in East Asia enrolled in the phase 3 clinical trials. In two induction studies (U-EXCEL [NCT03345849], U-EXCEED [NCT03345836]), adults with moderately to severely active CD were randomized 2:1 to once-daily upadacitinib 45 mg or placebo for 12 weeks. In the 52-week U-ENDURE maintenance study (NCT03345823), patients with clinical response to upadacitinib induction therapy were rerandomized 1:1:1 to once-daily upadacitinib 15 mg, upadacitinib 30 mg, or placebo. Data from patients in East Asia were evaluated. In the induction studies, achievement of clinical and endoscopic outcomes occurred at higher rates with upadacitinib vs placebo at week 12 among the 204 patients in East Asia. Clinical remission per CD Activity Index (CDAI) and endoscopic response were achieved by 50.7% vs 20.6% and 61.8% vs 10.3% of patients in the upadacitinib 45-mg vs placebo groups, respectively. Similar trends for upadacitinib vs placebo were observed for the 117 patients in the maintenance study. Clinical remission per CDAI and endoscopic response were achieved by 41.5%, 54.8%, 8.8%, and 28.6%, 45.2%, 5.9% of patients receiving upadacitinib 15 mg, upadacitinib 30 mg, and placebo, respectively. The safety profile of upadacitinib was consistent with the global phase 3 population. Upadacitinib was efficacious in treating moderately to severely active CD among patients in East Asia and demonstrated a favorable benefit-risk profile.

PMID 42669112
Read full article →
PubMedMicrobial cell factories2026-08-30

Recombinant thermotolerant alkaline lipase from Lysinibacillus fusiformis for detergent and hard (Ras) cheese applications: cloning, expression, molecular docking, and characterization.

El-Sayed Ghada M GM, Wehaidy Hala R HR, Kholif Adel M M AMM, Salama Walaa H WH et al.

Thermostable and alkaline lipases are of significant interest for industrial applications, particularly in detergents and food processing. This study aimed to isolate, clone, and express lipase-encoding genes from a potent bacterial source to produce a thermo-tolerant alkaline lipase with enhanced catalytic efficiency and practical applicability. Among several bacterial isolates, the most potent lipase producer was identified as Lysinibacillus fusiformis, and its 16 S rRNA sequence was deposited in GenBank (PP757498). Three lipase-encoding genes (est, est2, and lipA) were successfully isolated, cloned, and heterologously expressed in Escherichia coli BL21 (DE3). Their sequences were submitted to GenBank under accession numbers PX136937.1, PX136938.1, and PX136936.1, respectively. The recombinant lipase encoded by lipA (rLipase) exhibited the highest activity (150 U/mL) compared with the native enzyme (56.2 U/mL). Molecular docking analysis demonstrated strong binding affinity of rLipase toward major fatty acid derivatives in olive oil, with the highest affinity for linoleic acid (- 8.0 kcal/mol), followed by oleic acid (- 7.8 kcal/mol) and palmitic acid (- 7.3 kcal/mol). These interactions were stabilized by hydrophobic interactions and hydrogen bonding, with key contributions from critical amino acid residues, particularly VAL250. The partially purified recombinant lipase (rLipase) exhibited a maximum activity of 320 U/mL at 80 °C and pH 9, demonstrating remarkable thermostability and alkaline tolerance. Functional evaluation showed that rLipase improved the detergent efficiency for oil stain-removal from cotton fabrics. In addition, supplementation with 0.4% rLipase accelerated Ras cheese ripening by shortening the maturation period from 120 to 90 days with maintaining the desired ripening process. The recombinant lipase from Lysinibacillus fusiformis demonstrated high thermal stability, alkaline tolerance, and strong catalytic efficiency. Its effectiveness in detergent formulations and cheese ripening highlights its potential as a versatile industrial biocatalyst for lipid bioconversion and related applications.

PMID 42668381
Read full article →
PubMedAdsorption : journal of the International Adsorption Society2026-08-30

A reference low-pressure CO2 adsorption isotherm for zeolite 13X: results of an interlaboratory study.

Nguyen Huong Giang T HGT, Newton David D, Ahmad Riaz R, Prinz Carsten C et al.

This paper reports the results of an international interlaboratory study sponsored by the Versailles Project on Advanced Materials and Standards (VAMAS) and led by the National Institute of Standards and Technology (NIST) on the measurement of low-pressure CO2 adsorption isotherms at 25 °C on zeolite 13X (NIST research grade test material 10257). Eighteen laboratories participated in the study and contributed 21 datasets. From these data, a consensus reference isotherm, along with the 95% uncertainty interval (U k=2 ), were determined and reported. Results indicate the material is suitable for development into NIST reference material, which will become the first zeolitic reference material in beaded form at NIST. The online version contains supplementary material available at https://doi.org/10.1007/s10450-026-00701-3.

PMID 42668753
Read full article →
PubMedActa neurologica Belgica2026-08-30

Cardiac cephalalgia: an underrecognized cause of secondary headache - a retrospective study.

Sarıkaya Cansu C, Salkın Fatma Özge FÖ, Sarıkaya Caner C, Selekler H Macit HM

Cardiac cephalalgia is a type of secondary headache that occurs in association with myocardial ischemia. It may present without typical chest pain, complicating early diagnosis and delaying optimal treatment. This study aims to evaluate the frequency of headache in a selected cohort of patients with myocardial infarction undergoing coronary angiography. We retrospectively reviewed 115 patients diagnosed with MI who underwent coronary angiography. The presence of headache prior to angiography was recorded, and follow-up was performed to assess its persistence after intervention. Statistical analyses included Chi-square, Mann-Whitney U and McNemar tests to evaluate associations between headache and clinical/laboratory parameters. A total of 90 patients were included in the study (mean age 57.8 years; 71 males). Among them, 27 patients (30%) experienced headache prior to angiography. Following coronary intervention, headache persisted in only one patient, indicating a statistically significant reduction (p < 0.001). No significant relationship was found between headache presence and MI type (STEMI vs. NSTEMI), age, LDL cholesterol, blood pressure or other clinical parameters (p > 0.05). Cardiac cephalalgia may be an overlooked presentation of myocardial infarction, occurring in a subset of patients. The complete resolution of symptoms following revascularization underscores the need to consider cardiac cephalalgia in the differential diagnosis of unexplained headaches, especially in the absence of classic cardiac symptoms. Greater clinical awareness could improve early diagnosis and patient outcomes.

PMID 42669089
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about SH-U-454